Relay Therapeutics, Inc.

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Relay Therapeutics Inc (NASDAQ: RLAY) has announced an interim data Phase 1 trial of RLY-4008 in FGFR2-altered cholangiocarcinoma (bile duct cancer) and multiple other solid tumors.  The data were shared at the AACR-NCI-EORTC Molecular Targets Conference.

Relay Therapeutics Highlights Interim Data From Bile Duct Cancer Trial

Interim data suggest that RLY-4008 is a highly selective FGFR2 inhibitor that has not shown to be limited by off-target toxicities of hyperphosphatemia (FGFR1) and diarrhea (FGFR4)

Relay Therapeutics Announces Interim Clinical Data that Support RLY-4008 as a Highly Selective FGFR2 Inhibitor

RLY-2608 preferentially binds mutant PI3Kα at a novel allosteric site discovered by the Dynamo™ platform

Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα

Relay Therapeutics to host a conference call on October 8th at 12:30 pm E.T. Relay Therapeutics to host a conference call on October 8th at 12:30 pm E.T.

Relay Therapeutics to Present Clinical Data on RLY-4008 and Preclinical Data on RLY-2608 at AACR-NCI-EORTC Molecular Targets Conference

CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, plans to report second quarter 2021 financial results after the close of market on Thursday, August 12, 2021. The company will not be conducting a teleconference in conjunction with its financial results press release.

Relay Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Highlights

CAMBRIDGE, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit on Thursday May 20, 2021 at 11:20am ET. The fireside chat will be webcast live and may be accessed from the Investor page of Relay's website under Events and Presentations. Within 24 hours following the fireside chat, an archived replay of the webcast will be available until August 18, 2021.

Relay Therapeutics to Participate in Fireside Chat at the Cowen 2nd Annual Oncology Innovation Summit

CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, today reported first quarter 2021 financial results.

Relay Therapeutics Reports First Quarter 2021 Financial Results

Dr. Riley brings extensive experience in artificial intelligence with a focus on drug discovery Dr. Riley brings extensive experience in artificial intelligence with a focus on drug discovery

Relay Therapeutics Strengthens Computational Leadership Team with Addition of Patrick Riley, Ph.D.

CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Bank of America 2021 Health Care Conference on Tuesday, May 11, 2021 at 8:45 a.m. ET. The fireside chat will be webcast live and may be accessed from the Investor page of Relay's website under Events and Presentations. Within 24 hours following the fireside chat, an archived replay of the webcast will be available until August 13, 2021.

Relay Therapeutics to Participate in Fireside Chat at Bank of America 2021 Health Care Conference

Ms. O'Meara and Dr. Ferté bring extensive experience in drug development across oncology and genetic disease Ms. O'Meara and Dr. Ferté bring extensive experience in drug development across oncology and genetic disease

Relay Therapeutics Expands Clinical Leadership Team with Addition of Tara O'Meara and Charles Ferté

Relay Therapeutics Inc (NASDAQ: RLAY) recently announced it is buying ZebiAI. These are the details about the deal.

Why Relay Therapeutics (RLAY) Is Buying ZebiAI

Relay Therapeutics' leadership in this new breed of biotech positions the company as  a strategic partner of choice for emerging technologies and founders in these fields

Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAI

Advanced two programs, RLY-1971 and RLY-4008, into clinical development, and on track to initiate IND enabling studies with PI3Kα mutant selective inhibitor in 2021

Relay Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

RLY-4008 demonstrates strong activity against known clinical on-target resistance mutations in cellular and in vivo preclinical models RLY-4008 demonstrates strong activity against known clinical on-target resistance mutations in cellular and in vivo preclinical models

Relay Therapeutics to Present Preclinical Data on RLY-4008 at AACR Annual Meeting

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day on Thursday, February 11, 2021 at 3:30 p.m. ET. The fireside chat will be webcast live and may be accessed from the Investor page of Relay's website under Events and Presentations. Within 24 hours following the fireside chat, an archived replay of the webcast will be available for up to one year.

Relay Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2021 Oncology Day

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 4:30 p.m. ET. The presentation will be webcast live and may be accessed from the Investor page of Relay's website under Events and Presentations. An archived replay of the webcast will be available for at least 30 days following the presentation.

Relay Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

Collaboration brings together clinical stage SHP2 and KRAS G12C inhibitors

Relay Therapeutics Announces a Worldwide License and Collaboration Agreement with Genentech for RLY-1971

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today reported third quarter 2020 financial results.

Relay Therapeutics Reports Third Quarter 2020 Financial Results

Relay Therapeutics: Heavily Backed Biotech Brains Trust Looks A Long-Term Buy

CAMBRIDGE, Mass., Sept.  03, 2020  (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today announced the first patient has been dosed in a first-in-human clinical trial of RLY-4008 enriched for patients with intrahepatic cholangiocarcinoma (ICC) and other advanced solid tumors harboring a fibroblast growth factor receptor 2 (FGFR2) alteration. RLY-4008 is the only selective small molecule inhibitor of FGFR2 in clinical development.

Relay Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Trial of RLY-4008, a Highly Selective FGFR2 Inhibitor

CAMBRIDGE, Mass., Aug.  27, 2020  (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today reported second quarter 2020 financial results.

Relay Therapeutics Reports Second Quarter 2020 Financial Results

CAMBRIDGE, Mass., July  20, 2020  (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today announced the closing of its initial public offering of 23,000,000 shares of its common stock, including 3,000,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $20.00 per share. The gross proceeds of the offering were $460.0 million, before deducting underwriting discounts and commissions and other offering expenses. The shares began trading on the Nasdaq Global Market on July 16, 2020 under the symbol “RLAY.” All shares in the offering were offered by Relay Therapeutics.

Relay Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

TAIPEI, Taiwan--(BUSINESS WIRE)--Oak Stone Limited says SoftBank-backed Relay Therapeutics has soared 75% in its trading debut, expanding its IPO to raise $400 million.

Oak Stone Limited Says Relay Therapeutics IPO Soars In Trading Debut

Shares of Relay Therapeutics Inc. RLAY, +67.10% sprinted out of the gate Thursday, after the clinical-stage oncology company's upsized initial public offering priced above the expected range.

Relay Therapeutics's stock sprints out of the gate, after upsized IPO priced above recently raised expectations

Relay Therapeutics raised $400 million with an initial public offering that priced late Wednesday and surpassed expectations. The Relay Therapeutics IPO will begin trading Thursday morning.

News for Relay Therapeutics, Inc. Stock (RLAY)